Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P 276

Drug Profile

P 276

Alternative Names: P-276-00; P276; Riviciclib

Latest Information Update: 11 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Piramal Life Sciences
  • Developer Piramal Enterprises; Piramal Healthcare
  • Class Antineoplastics; Chromans; Pyrrolidines
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Head and neck cancer; Malignant melanoma; Mucositis; Multiple myeloma; Pancreatic cancer
  • Discontinued Mantle-cell lymphoma; Solid tumours

Most Recent Events

  • 01 Sep 2014 Piramal terminates phase I/II trial in Breast cancer (combination therapy, metastatic disease, triple-negative disease) in USA (NCT01333137)
  • 01 Sep 2014 Piramal completes a phase I/II trial in the prevention of Radiation-induced mucositis in patients with locally advanced head and neck cancer receiving chemotherapy in India (NCT01903018)
  • 18 Jul 2013 Piramal completes enrolment in its phase II trial for Breast cancer (combination therapy, metastatic disease, triple-negative disease) in USA (NCT01333137)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top